Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...
Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual...
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm...
Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval
China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the...
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage...
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc....
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
Hainan Poly Pharm’s Generic ProHance Wins FDA Approval in US
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced that the US Food and Drug...
Kexing Biopharm and Bio-Thera Solutions Form Alliance for Global Expansion
China-based Kexing Biopharm (SHA: 688136) and Bio-Thera Solutions Ltd (SHA: 688177) have formed a strategic...
MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...
Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal
Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...
Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial
China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...